Savara (SVRA) EBITDA Margin (2013 - 2020)

Savara's (SVRA) quarterly EBITDA Margin came in at 1301200.0% in Q4 2020, down 30786.16% on a QoQ basis from 4212.89% in Q3 2020.

Savara (SVRA) EBITDA Margin (2013 - 2020) Analysis & Trends

Savara (SVRA) has 5 years of EBITDA Margin data on file, last reported at 1301200.0% in Q4 2020.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 1301200.0% in Q4 2020; TTM through Mar 2022 was 3910900.0%, a N/A change from a year earlier, with the FY2020 full-year figure at 19182.88%, changed N/A from the prior year.
EBITDA Margin for Q4 2020 stood at 1301200.0%, down from 4212.89% in the prior quarter.
Over the last five years, EBITDA Margin for SVRA reached as high as 9939.36% in Q2 2017 and fell as low as 1301200.0% in Q4 2020.
Historically, EBITDA Margin has averaged 218123.51% across 3 years, with a median of 4645.81% in 2017.
On a YoY basis, EBITDA Margin climbed as much as 1697789 bps in 2016 and fell as far as 1697789 bps in 2016.
Year by year, EBITDA Margin stood at 1011.0% in 2016, then surged by 1083 bps to 9939.36% in 2017, then slumped by 13191 bps to 1301200.0% in 2020.
Per Business Quant data, the three most recent EBITDA Margin figures were 1301200.0% in Q4 2020, 4212.89% in Q3 2020, and 9939.36% in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Savara	1.24 Bn	1.24 Bn	-	-

Download Data